Diphosphonate treatment of Paget's disease

Diphosphonate treatment of Paget's disease

Finerman GA; Gonick HC; Smith RK; Mayfield JM

Clinical Orthopaedics and Related Research

1976

Female; Humans; Male; Aged; Middle Aged; Clodronate; Alkaline Phosphatase/blood; Fractures; Bone/etiology; Diphosphonates/administration & dosage/adverse effects/therapeutic use; Osteitis Deformans/drug therapy/metabolism/radiography; Osteomalacia/etiology; Proline/urine

Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) was administered in a dose of 20 mg/kg/d to 21 patients with symptomatic Paget's disease. All patients were treated for 6 months and then followed for an additional 6 months. There was a striking decline in serum alkaline phosphatase and urinary hydroxy-proline excretion observed after 3 months of therapy which was not significantly improved in the succeeding 3 months. Concomitantly there was marked improvement in clinical symptoms and bone scans. Following cessation of therapy, continued biochemical and clinical evidence of remission persisted. Several patients on repeat treatment with EHDP appeared to respond promptly. Side effects were minimal except for a possibly related osteomalacia and increased incidence of pathologic fractures.

1976

Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).

Journal Article

Backlog